Cargando…
Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance
BACKGROUND: While BMPR2 mutation strongly predisposes to pulmonary arterial hypertension (PAH), only 20% of mutation carriers develop clinical disease. This finding suggests that modifier genes contribute to FPAH clinical expression. Since modifiers are likely to be common alleles, this problem is n...
Autores principales: | West, James, Cogan, Joy, Geraci, Mark, Robinson, Linda, Newman, John, Phillips, John A, Lane, Kirk, Meyrick, Barbara, Loyd, Jim |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561034/ https://www.ncbi.nlm.nih.gov/pubmed/18823550 http://dx.doi.org/10.1186/1755-8794-1-45 |
Ejemplares similares
-
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension
por: Johnson, Jennifer A, et al.
Publicado: (2009) -
Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension
por: Austin, Eric D, et al.
Publicado: (2009) -
BMPR2 expression is suppressed by signaling through the estrogen receptor
por: Austin, Eric D, et al.
Publicado: (2012) -
Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension
por: West, James, et al.
Publicado: (2020) -
The genetics of pulmonary arterial hypertension in the post-BMPR2 era
por: Fessel, Joshua P., et al.
Publicado: (2011)